Objective: Chronic nonhealing wounds are a major health problem for patients in the United States and worldwide. Diabetes and ischemia are two major risk factors behind impaired healing of chronic lower extremity wounds. Poly-ADPribose polymerase (PARP) is found to be overactivated with both ischemic and diabetic conditions. This study seeks a better understanding of the role of PARP in ischemic and diabetic wound healing, with a specific focus on angiogenesis and vasculogenesis. Methods: Ischemic and diabetic wounds were created in FVB/NJ mice and an in vitro scratch wound model. PARP inhibitor PJ34 was delivered to the animals at 10 mg/kg/d through implanted osmotic pumps or added to the culture medium, respectively. Animal wound healing was assessed by daily digital photographs. Animal wound tissues, peripheral blood, and bone marrow cells were collected at different time points for further analysis with Western blot and flow cytometry. Scratch wound migration and invasion angiogenesis assays were performed using human umbilical vein endothelial cells (HUVECs). Measurements were reported as mean 6 standard deviation. Continuous measurements were compared by t-test. P < .05 was considered statistically significant. Results: A significant increase in PARP activity was observed under ischemic and diabetic conditions that correlated with delayed wound healing and slower HUVEC migration. The beneficial effect of PARP inhibition with PJ34 on ischemic and diabetic wound healing was observed in both animal and in vitro models. In the animal model, the percentage of wound healing was significantly enhanced from 43% 6 6% to 71% 6 9% (P < .05) by day 7 with the addition of PJ34. PARP inhibition promoted angiogenesis at the ischemic and diabetic wound beds as evidenced by significantly higher levels of endothelial cell markers (vascular endothelial growth factor receptor 2 [VEGFR2] and endothelial nitric oxide synthase) in mice treated with PJ34 compared with controls. Flow cytometry analysis of peripheral blood mononuclear cells showed that PARP inhibition increased mobilization of endothelial progenitor cells (VEGFR2
D

/CD133
D and VEGFR2 D /CD34 D ) into the systemic circulation. Furthermore, under in vitro hyperglycemia and hypoxia conditions, PARP inhibition enhanced HUVEC migration and invasion in Boyden chamber assays by 80% and 180% (P < .05), respectively. Conclusions: Delayed healing in ischemic and diabetic wounds is caused by PARP hyperactivity, and PARP inhibition significantly enhanced ischemic and diabetic wound healing by promoting angiogenesis. (J Vasc Surg 2017;65:1161-9.) Clinical Relevance: Chronic nonhealing wounds, a major health problem in the United States, affect 6.5 million people and cost $25 billion annually. The two major risk factors of poor wound healing are arterial occlusive disease and diabetes. Because 40% of diabetics also have arterial occlusive disease, the people with combined ischemic and diabetic wounds have the highest risk for limb loss. Biologic treatment to enhance angiogenesis through gene and cellular therapy has been studied extensively to promote limb salvage. A better understanding of the mechanisms behind poor healing in diabetic and ischemic wounds is needed for the identification of new treatment targets. Chronic nonhealing wounds, a major health problem in the United States, affect 6.5 million people and cost $25 billion annually. 1 The two major risk factors that contribute to poor wound healing are arterial occlusive disease and diabetes. 2 Based on the National Diabetes Statistics Report from the Centers for Disease Control and Prevention in 2014, approximately 29 million people or 9.3% of the U.S. population suffer from diabetes. Furthermore, up to 25% of diabetics develop a foot ulcer, which could result in 71,000 major leg amputations annually. 3 The cost for diabetic-related amputations is as high as $3 billion per year. 4 Because 40% of diabetics also have arterial occlusive disease, the people with combined ischemic and diabetic wounds are at the highest risk for limb loss. 5 Unfortunately, surgical revascularization is not feasible in every patient. As a result, in addition to optimal wound care, biologic treatment to enhance angiogenesis through gene and cellular therapy has been studied extensively to promote limb salvage. Early-phase clinical trials that involved gene therapy using fibroblast growth factor 6 and hepatocyte growth factor 7 plasmids and cellular therapy using autogenous or allogeneic bone marrow stem cells 8 yielded early promising results, but there have been no phase 3 trials showing definitive efficacy of these therapies. To identify new treatment targets to enhance healing, the mechanisms behind poor healing in diabetic and ischemic wounds need to be better understood.
Poly-ADP-ribose polymerase (PARP) is a nuclear enzyme that is involved in cellular injury and tissue regeneration. We selected PARP as our molecule of interest to study because PARP is pathologically overactivated in both diabetic and ischemic conditions. [9] [10] [11] [12] [13] The role of PARP in wound healing has been previously explored in the setting of chronic nonhealing wounds due to radiation 14 and in corneal epithelial healing in diabetic rats, 15 in which PARP was found to be overactivated. PARP inhibition proved to be beneficial to wound healing in both of these settings. In this study, we were specifically interested in the role of PARP in delayed healing of cutaneous ischemic and diabetic wounds, which has not been well elucidated.
One major factor behind poor healing of ischemic and diabetic wounds is the impaired endogenous neovascularization at the wound beds in diabetic subjects. In an adult, neovascularization at the wound bed occurs by two parallel processes: (1) angiogenesis, whereby new blood vessels are formed from resident endothelial cells; and (2) vasculogenesis, which involves mobilization and homing of the endothelial progenitor cells (EPCs) from the bone marrow to the wound beds. Vasculogenesis is suppressed in diabetic subjects because of a decreased number of EPCs as well as an impaired EPC mobilization/homing capability caused by suppression of the endothelial nitric oxide synthase (eNOS)-nitric oxide pathway. 16 PARP inhibition prevents hyperglycemia-induced impairment of angiogenesis during wound healing in a zebrafish model. 10 Because the direct role of PARP in angiogenesis in the context of ischemic and diabetic wound healing has not been well elucidated, this study seeks a better understanding of the role of PARP in ischemic and diabetic wound healing, with a specific focus on angiogenesis and vasculogenesis.
METHODS
In vitro scratch wound assay. The scratch wound migration assay was performed with human umbilical vein endothelial cells (HUVECs) that were purchased from ATCC (Manassas, Va) and cultured in endothelial growth medium-2 (EGM-2; Lonza, Walkersville, Md). The cells were cultured to confluence in a hyperglycemic medium (20 mM glucose) and incubated in a hypoxic (2% oxygen) chamber to simulate diabetic and ischemic conditions, respectively. Four different culture environments were used: normal (EGM-2 incubated in a standard incubator), hyperglycemic (added glucose to 20 mM in EGM-2 in a standard incubator), hypoxic (EGM-2 in a hypoxic chamber), and combined hyperglycemic/hypoxic (20 mM glucose in EGM-2 in a hypoxic chamber). A sterile pipette tip was used to make a uniform scratch. Ten different scratch wounds were made for each group. Cells were photographed under inverted microscopy, and the distance of cellular migration across the gap was measured using ImageJ software (National Institutes of Health, Bethesda, Md). HUVECs were collected, and cellular PARP activity from the cell lysates was measured by detecting the end product of PARP enzyme, poly-ADP-ribose (PAR), by Western blot.
The water-soluble PARP inhibitor PJ34 (Tocris Biosciences, Bristol, UK) was used to assess the effect of PARP inhibition on cellular migration across the gap. Different concentrations were used (2.5 mM, 5 mM, 7.5 mM, 10 mM) 17 to test the dosage-dependent effect of PJ34 on cellular migration. PARP inhibitor was added right after the scratch wounds were made.
Animal protocol. To confirm what was observed in the in vitro scratch wound assay, an established murine model 16 of acute diabetic/ischemic wounds was used to investigate the role of PARP in poor healing. Animal care and experimental procedures were in compliance with the principles of laboratory animal care (Guide for the Care and Use of Laboratory Animals, National Institutes of Health Publication 86- 23, 1985) and approved by the institutional review committee. Male FVB/NJ and PARP-1 knockout and PARP-1 wild-type mice (8-12 weeks old) were acquired from Jackson Laboratory (Bar Harbor, Me). FVB/ NJ was chosen for this study because this strain was used by many previous investigators in this well-established model of ischemic/diabetic wound healing. 18 Diabetes was induced by injection of streptozocin (Sigma-Aldrich, St. Louis, Mo; 60 mg/kg in 50 mM sodium citrate intraperitoneally daily for 5 days). Mice were considered diabetic when the serum glucose level obtained from blood taken from the tail vein was above 250 mg/dL. Mice were rested for 2 weeks before undergoing surgery whereby ischemia was achieved by femoral artery ligation. 16 Ischemia of the legs was verified by laser Doppler scanning. A full-thickness wound was created on the ventral surface of the thigh using a 3-mm punch biopsy device. The progress of wound healing was monitored by daily digital photographs, and the wound surface areas were measured by ImageJ. Wound healing was quantified as % wound closure ¼ [(Area of original wound À Area of actual wound)/Area of original wound] Â 100.
Initially, four different groups were studied: normal (nonischemic, nondiabetic), ischemic, diabetic, and combined ischemic and diabetic. Ten different animals were used in each group. The wound tissues were collected at different time points (day 1, 4, 7, 10, 14), and PARP activity in the tissues was measured using Western blot. Subsequently, when the PARP inhibitor PJ34 was used to test the effect of PARP inhibition on wound healing, we used all ischemic and diabetic wounds. The mice with ischemic and diabetic wounds were treated with either normal saline or 10 mg/kg/d of PJ34. 11 The reagents were delivered through osmotic pumps that were implanted intraperitoneally.
Bone marrow cells were also collected from both femurs and tibias at different time points (day 1, 4, 7, 10, 14). The muscles were cleaned off from the bones, and the bone marrow cells were flushed out with phosphatebuffered saline using a 10-mL syringe with a 25-gauge needle. The bone marrow suspension was aspirated repeatedly using a 10-mL syringe with an 18-gauge needle to produce a single-cell suspension and then passed through a 70-mm cell strainer. The cells were then spun down and washed with phosphate-buffered saline. PARP activity from the bone marrow cells was measured by Western blot.
Immunohistochemistry. Wound tissues collected from the ventral surface of the thigh were fixed in formalin and paraffin embedded. Immunostaining was carried out using 7-mm formalin-fixed, paraffin-embedded sections. Deparaffinized tissue sections were subjected to heat antigen retrieval in pH 9 ethylenediaminetetraacetic acid-based buffered solution. Endogenous peroxidase was quenched. A mouse monoclonal anti-PAR antibody (Trevigen, Gaithersburg, Md) was used at 1:300 dilution at 4 C overnight, followed by incubation with a goat anti-mouse antibody conjugated with horseradish peroxidase at 1:1000 dilution. Sections were then visualized with 3,3 0 -diaminobenzidine and counterstained with hematoxylin.
Western blot. Total protein was extracted from mouse wound tissue by homogenization in 1 mL of mammalian protein extraction buffer (GE Healthcare Bio-Science Corp, Piscataway, NJ) and cleared by centrifugation at 12,000Â g for 10 minutes; 20 mg of protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted onto Immun-Blot polyvinylidene difluoride membrane (Bio-Rad, Hercules, Calif). The membrane was then blocked with 5% nonfat dry milk and incubated with primary antibodies (Trevigen anti-PAR C followed by incubation with horseradish peroxidase-conjugated anti-rabbit (VEGFR2) or anti-mouse (eNOS, PAR) secondary antibodies (LI-COR, Lincoln, Ne). Immune complexes were detected on film using Pierce ECL Western Blotting Substrate (Thermo Scientific, Rockford, Ill).
Flow cytometry. Four days after wounding, the animals were euthanized, and peripheral blood mononuclear cells were collected as described previously. 19 Mononuclear cells were first isolated from blood by gradient centrifugation at 250Â g for 30 minutes using Histopaque 1083 (Sigma-Aldrich) and then subjected to red cell lysis and Fc blockade (CD16/CD32; BD Pharmingen, San Diego, Calif). Mononuclear cells were analyzed by flow cytometry (LSR II; Becton Dickinson, Franklin Lakes, NJ). The presence of EPCs in the circulation was detected using the following markers: Flk1 (VEGFR2 in mice), CD34 (immature endothelial cell markers), and CD133 (immature hematopoietic stem cells). The antibodies used were APC-conjugated anti-FLK1 (Avas12a1; eBioscience, San Diego, Calif), APC-Cy7-conjugated anti-CD34 (581; BioLegend, San Diego, Calif), and PE-Cy7 conjugated anti-CD133 (315-2C11, BioLegend). There were 200,000 events acquired; the live cell population in the forwardscatter vs side-scatter window was gated, and doublepositive cells were expressed as a percentage of total cells.
Cell migration and invasion assay. Cell migration and invasion were measured in a 96-well basement membrane extract (BME) Cell Invasion Assay Kit (Trevigen) according to the manufacturer's protocol. Briefly, cultured HUVECs were starved in serum-free medium for 24 hours before harvesting, harvested, and then seeded (50,000/well) into the top chambers coated with various concentrations of BME or without BME. The bottom chambers were filled with complete EGM-2 medium. The HUVECs were then incubated in a cell culture chamber for 4 hours for the cell migration assay or for 24 hours for the cell invasion assay. The cells that migrated to the bottom side of the membrane were dissociated from the membrane and stained with calcein AM. Fluorescence was measured with a Fluoroskan Ascent fluorometer (Thermo Scientific).
Statistical analysis. Measurements were reported as mean 6 standard deviation. Continuous measurements were compared by a t-test. P < .05 was considered statistically significant.
RESULTS
The delayed healing of ischemic or diabetic wounds is associated with increased PARP activity in vitro and in vivo
In vitro model, scratch wound migration assay. Hyperglycemia or hypoxia did not alter cellular adhesion or cellular death. At 24 hours, the gap almost completely closed in the presence of standard culture medium, whereas quantitative analysis of the cell migration distance showed a significant delay of gap closure in cells cultured under hyperglycemic or hypoxic conditions (Fig 1) . The cellular migration distance for HUVECs under standard condition was 695 6 101 mm compared with 380 6 52 mm, 391 6 60 mm, and 252 6 48 mm for hyperglycemic, hypoxic, and combined hyperglycemic/hypoxic conditions, respectively (n ¼ 10 in each group; P < .05 for the last three groups vs normal control; Fig 1) . Furthermore, delayed migration of cells under hyperglycemic/ hypoxic conditions was associated with increased PARP hyperactivity (percentage b-actin was 13% 6 6% in normal vs 21% 6 4%, 27% 6 5%, and 28% 6 3% for hyperglycemic, hypoxic, and combined hyperglycemic/hypoxic, respectively; n ¼ 10 in each group; P < .05 for the last three groups vs normal control; Fig 1) . These studies show that increased PARP activity is associated with reduced cell migration.
Animal model. Whereas most normal wounds healed by day 7, the ischemic and diabetic wounds exhibited minimal healing at this time point (Fig 2) . Western blot analysis of wound tissues as well as immunohistochemistry staining showed significantly higher levels of PARP activity in ischemic and diabetic mice compared with the normal mice. When both conditions were present, PARP activity increased even more than that of either condition alone (Fig 2) . PARP activity measured as percentage of b-actin was 41% 6 2% in the normal group vs 70% 6 5% in the ischemic group, 62% 6 2% in the diabetic group, and 139% 6 6% in the combined ischemic/diabetic group (n ¼ 10 in each group; P < .05 for normal vs the last three groups; Fig 2) . Thus, increased PARP activity is associated with delayed wound healing.
PARP inhibition enhanced ischemic or diabetic wound healing in both in vitro and animal models
In vitro model. Addition of the PARP inhibitor PJ34 effectively suppressed cellular PARP activity in HUVECs cultured in the hyperglycemic/hypoxic condition as shown by immunohistochemistry staining in Fig 3. Although PARP inhibition did not affect cellular proliferation during the first 24 hours, it enhanced cellular migration across the scratch wound compared with untreated control from 266.8 6 32.8 mm to 341.7 6 45 mm (n ¼ 10; P < .05; Fig 3) . Thus, PARP inhibition under diabetic/ischemic conditions increases cell migration.
Animal model. At day 7, an untreated ischemic/diabetic wound healed by 43% 6 6% of the original wound size, whereas the addition of PJ34 increased the healing level to 71% 6 9% (n ¼ 10; P < .05; Fig 3) . Likewise, untreated PARP-1 knockout mice also showed moderate improvement of wound healing (68% 6 9%) compared with untreated wild-type controls (56% 6 5%; n ¼ 10; P < .05). These studies show that reduction of PARP activity improves the rate of wound healing.
PARP inhibition normalized PARP activity in diabetic bone marrow and enhanced EPC mobilization into the circulation
We suspected that PARP hyperactivity in diabetic mice was not limited to wound tissues only because diabetes is a systemic condition. We studied PARP activity in the bone marrow cells because we were interested in whether PARP has a role in mobilization of the bone marrow cells (EPCs) into the wound beds during vasculogenesis. Indeed, diabetic bone marrow also exhibited significantly higher PARP activity compared with nondiabetic bone marrow (percentage b-actin was 56% 6 12% vs 27% 6 5%; P < .05, respectively; Fig 4) . Diabetic animals treated with PJ34 exhibited a nearly normal level of PARP activity Cellular migration and poly-ADP-ribose polymerase (PARP) activity in the in vitro scratch wound assay using human umbilical vein endothelial cells (HUVECs). Photographs of scratch wounds taken at 24 hours showed nearly complete gap closure in standard culture medium (A). Scratch wounds cultured in hypoxic (B), hyperglycemic (C), and hyperglycemic/hypoxic (D) conditions showed significantly delayed gap closure, which is quantified in the middle bar graph (original magnification Â40). Delayed cell migration (E) was associated with increased PARP activity as measured by Western blot (F). PAR, Poly-ADP-ribose. * P < .05 vs normal.
in bone marrow cells (percentage b-actin was 33% 6 4%).
As a result, mice treated with PJ34 mobilized more EPCs in the circulation compared with that in the circulation of untreated mice. The percentage of VEGFR2 þ /CD133 þ cells measured by flow cytometry in the peripheral blood increased from 0.074% for untreated animals with ischemic/diabetic wounds to 0.62% when the animals were treated with the PARP inhibitor. Likewise, the percentage of VEGFR2 þ /CD34 þ cells in the circulation increased from 0.10% to 1.27% when the animals were treated with PJ34 (Fig 4) . Thus, PARP inhibition effectively reduces PARP activity and greatly increases EPCs in the circulation. The increase in progenitor cells with PARP inhibition would explain in part the increased dermal healing due to potentially increased angiogenesis seen with PARP inhibition. We next examined the effects of PARP inhibition on some of the steps in angiogenesis and on angiogenesis in the wounds.
PARP inhibition enhanced endothelial cell migration and invasion
PJ34 at different concentrations significantly enhanced HUVEC migration across the membrane in the Boyden chamber. The best effect was observed at 2.5 mM PJ34, which enhanced migration by 80%. When basement membrane-like matrix (BME/Matrigel) was used to test the invasion of HUVECs across a coated membrane in the Boyden chamber, 2.5 mM PJ34 increased invasion by 180% (Fig 5) . There was little additional effect at concentrations higher than 2.5 mM.
PARP inhibition enhanced angiogenesis at the wound beds
Angiogenesis at the wound beds of ischemic/diabetic mice was measured by Western blot analysis of the endothelial cell markers VEGFR2 and eNOS. There was a twofold increase in VEGFR2 when the animals were treated with PJ34 (P < .05). Likewise, the eNOS level was increased by threefold in treated animals compared with that in controls (P < .05; Fig 6) . Thus, because angiogenesis was increased by PARP inhibition, this may explain the effect of PARP inhibition on improving wound healing in animal models of diabetes.
DISCUSSION
Wound healing is a complex, well-orchestrated process that involves multiple carefully regulated steps, such as leukocyte infiltration (inflammation), epithelial and mesenchymal cell proliferation, angiogenesis, and interstitial matrix remodeling (contraction, maturation). 20 When any of Delayed wound healing in ischemic/diabetic mice was associated with poly-ADP-ribose polymerase (PARP) hyperactivity. Photographs of wounds taken on day 7 in normal (nonischemic/nondiabetic) mice showed complete healing (A), whereas ischemic (B), diabetic (C), and ischemic/diabetic (D) wounds showed minimal healing. The bar graph showed that the delay in healing of ischemic and diabetic wounds was associated with PARP hyperactivity, which was measured by Western blot ( * P < .05 vs normal). Immunohistochemistry staining for PARP activity showed minimal nuclear staining in normal wounds (E) and very intense staining in the nuclei of ischemic (F), diabetic (G), and combined ischemic/diabetic (H) wounds (original magnification Â200; white arrows denote staining for PARP activity). PAR, Poly-ADP-ribose. these processes is impaired, healing is severely compromised. Diabetic wounds are notoriously difficult to heal because of the defects in angiogenesis, reepithelialization, and wound closure. 21 Angiogenesis is impaired not only at the microscopic level because of poorly controlled hyperglycemia, resulting in endothelial cell dysfunction, 12,13 but also at a macroscopic level because a significant percentage of diabetics also have superimposed ischemia due to arterial occlusive disease. Combined ischemia and diabetes cause severe stress to the body at the molecular and cellular levels and impede the normal wound healing process.
We confirmed that PARP activity was indeed markedly increased more than threefold in ischemic/diabetic wounds compared with that in nonischemic/nondiabetic wounds. Furthermore, we established the cause and effect relationship between PARP hyperactivation and poor wound healing by showing that PARP inhibition or deletion promoted ischemic/diabetic wound healing and that the healing was better in the PARP knockout mouse than in the wild-type animals. The enhanced healing could be detected as early as day 7, and the time to complete healing in animals treated with PARP inhibition was accelerated by 2 days. We chose to treat the animals systemically through an osmotic pump rather than by multiple intraperitoneal injections to achieve a more reliable and steady blood concentration of the inhibitor. Nevertheless, topical treatment with a cream filled with PARP inhibitor could be tested in the future because the local route is much more easily accepted as a treatment option in the clinic for patients with chronic nonhealing ischemic/diabetic wounds; however, the percentage of absorption through cutaneous delivery could be a rate-limiting step.
The beneficial effect of PARP inhibition on wound healing could be attributed to several different mechanisms, including downregulation of inflammatory cytokines and preservation of mitochondrial adenosine triphosphate content 14 that were well documented. In this study, we explored the potentially novel role of PARP in vasculogenesis and angiogenesis because this is the one aspect of the healing process that is severely impaired in ischemic/ diabetic wounds. Clinically, surgical revascularization is currently the best therapy to facilitate healing of chronic ischemic and diabetic lower extremity wounds; but even after revascularization, only 47% of the patients will heal their wounds with the current standard treatment, including débridement, moist dressings, infection control, and hyperbaric therapy. [21] [22] [23] [24] As a result, better medical therapy is needed to optimize the perfusion of these wounds. To discover new therapeutic targets, the mechanism behind impaired angiogenesis in ischemic and diabetic wounds needs to be investigated.
In an adult, part of the neovascularization at the wound comes from the mobilization and homing of the EPCs from the bone marrow to the wound beds, a process named vasculogenesis. The contribution of vasculogenesis to total neovascularization at the wound bed reported in the literature varies between 1% and 50%. 25 Vasculogenesis is known to be suppressed in diabetes because of a decreased number of EPCs as well as impaired EPC mobilization/homing capability due to suppression of the eNOS-nitric oxide pathway. 16 The role of PARP in this process is not well known. Nevertheless, it has been shown that PARP inhibition prevented hyperglycemia-induced The invasion assay was performed using 1Â BME/Matrigel. PARP inhibition with PJ34 resulted in significantly higher cell invasion across the membrane (bottom panel).
* P < .05 compared with 0 mM PJ34.
Fig 4.
Systemic poly-ADP-ribose polymerase (PARP) inhibition normalized PARP activity in diabetic bone marrow and enhanced mobilization of endothelial progenitor cells (EPCs) to the circulation. PARP activity of bone marrow cells was measured using Western blot (top panel). The cell markers vascular endothelial growth factor receptor 2 (VEGFR2)/CD133 and VEGFR2/ CD34 were used to detect EPCs in the peripheral blood using flow cytometry. PJ34-treated animals (bottom panels) showed a significantly higher percentage of EPCs in the peripheral blood compared with that of the untreated animals (middle panels). * Statistically significant with P < .05.
impairment of angiogenesis during wound healing in a zebrafish model. 10 Thus, PARP inhibition can be considered proangiogenic.
We discovered another potential cause behind the impaired mobilization of EPCs from the bone marrow to the systemic circulation. It appeared that PARP hyperactivity in diabetes is a systemic phenomenon because the bone marrow cells in diabetic mice exhibited significantly higher PARP activity than those of nondiabetic mice. When diabetic mice were treated with a PARP inhibitor, PARP activity was brought down to a nearly normal level. As a result, the mobilization of EPCs into the circulation was significantly enhanced. We identified EPCs in the peripheral blood by antigenic markers (CD34 and CD133) to define the stemness and hematopoietic lineage of the cells from the bone marrow and by Flk1 (or VEGFR2) to signify endothelial commitment. 26, 27 After EPCs are mobilized to the circulation, they migrate toward the wound bed to begin the neovascularization process. These cells need to attach, migrate, and invade the basement membrane to become the permanent endothelial cells at the site of the injury. In this study, we showed that PARP inhibitor enhanced the ability of HUVECs to migrate and to invade the basement membrane in the in vitro model. PARP inhibition enhanced angiogenesis at the wound bed evidenced by higher level of endothelial cell markers, such as VEGFR2 and eNOS.
Because vasculogenesis is a complex, multistep, difficult-to-control process, it may be more desirable to bypass the different stages of vasculogenesis by injecting autologous endothelial cells directly into the wound bed. Although multiple studies have shown a beneficial effect of injecting CD34 þ human cells directly into diabetic wounds in mice, [28] [29] [30] multiple clinical trials of this cellbased therapeutic angiogenesis for wound healing showed only limited clinical benefit. [31] [32] [33] For this cell-based therapy to be successful, the endothelial cells must attach to the extracellular matrix in the wound bed, migrate on the matrix, invade the matrix, form tube structures with polarized cells and tight cell junctions, and proliferate. As a result, multiple approaches for ex vivo modifications of autologous endothelial cells have been performed to enhance this process of capillary formation after injection. On the basis of our data regarding the enhanced migration and invasion of HUVECs with PARP inhibition, targeting of the PARP pathway by ex vivo modification of CD34 þ endothelial cells before direct delivery to the wound sites to enhance angiogenesis could be a promising treatment strategy.
CONCLUSIONS
PARP hyperactivity causes delayed healing in ischemic and diabetic wounds, and PARP inhibition enhanced healing by promoting angiogenesis. Targeting of PARP activity in ischemic and diabetic wounds could be a promising therapeutic approach to accelerate wound repair in the future. Nevertheless, a better understanding of the role of PARP in impaired angiogenesis of ischemic and diabetic wounds is 
